Romidepsin (FK228, Depsipeptide)

Catalog No.S3020 Synonyms: FR 901228, NSC 630176

Romidepsin (FK228, Depsipeptide) Chemical Structure

Molecular Weight(MW): 540.7

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 157 In stock
USD 477 In stock
USD 697 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • An HIV-Gag-SLYNTVATL-specific CTL clone was labeled with Alexa-Fluor555 conjugated cholera toxin subunit B either cultured with 500 nM SAHA or 25 nM romidepsin for 20 hours, or maintained as an untreated control. These effector cells were combined with SLYNTVATL peptide pulsed target cells, matched on the restricting allele, in a collagen matrix medium containing sytox green viability dye. These mixtures were then plated in three separate wells of an 8-well cover slip and imaged by time-lapse brightfield and fluorescent microscopy. A. Shown are representative fields of view from the no treatment (upper panel), 500 nM SAHA (middle panel), and 25 nM romidepsin (lower panel) conditions advancing in time from left to right. Time stamps are given in hh[ratio]mm format. Clones described in the results are indicated with yellow arrows and killed target cells are indicated with white arrows in the upper right panel.

    PLoS Pathog 2014 10(8), e1004287. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    PLZF-RARa–nonexpressing and -expressing PLZFRARβ3 cells were treated with 5 nmol/L romidepsin for the indicated time points. Induction of the DNA DSB marker γH2AX was measured by Western blotting. β-Actin was used as a loading control.

    Mol Cancer Ther 2013 12(8), 1591-604. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • Effects of combination of bort/romidepsin on HDAC6 inhibition and activation of ER stress signaling. HA cells were treated with combination of 15 nM bortezomib and 5 nM romidepsin or either drug alone for 24 hr. Expression of CHOP/GADD153 (green signals) and cleaved PARP (red signals) was detected by immunofluorescent staining. DAPI (blue signals) stained the cell nuclei.

    Int J Cancer 2014 135(12):2950-61. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    Impacts of chromopeptide A and FK228 on G2/M transition regulators. PC3 and LNCaP cells were treated with chromopeptide A or FK228 at indicated concentrations for 24 h, and cells lysates were immunoblotted with the indicated antibodies.

    Acta Pharmacol Sin, 2017, 38(4):551-560. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.
Features More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
Targets
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
In vitro

Unlike TSA, the active form redFK of Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively. Romidepsin is 17-23 times weaker than redFK in inhibiting these HDACs with IC50 of 36 nM, 47 nM, 510 nM, and 14 μM, respectively. Romidepsin treatment in HeLa cells induces histone acetylation and p21 expression with EC50 of 3.0 nM, more strongly than redFK with EC50 of 11 nM due to the instability of redFK. [1] In addition to G2/M arrest, Romidepsin treatment causes cyclin D1 downregulation and a p53-independent p21 induction, leading to inhibition of CDK and dephosphorylation of Rb resulting in growth arrest in the early G1 phase. [2] Romidepsin is 100 times more potent than TSA and 1,000,000 times more potent than butyrate in inhibiting the proliferation of the A549 cells. [3] Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. [5] Romidepsin promotes apoptosis in chronic lymphocytic leukemia (CLL) cells at a concentration corresponding to that at which H3 and H4 acetylation and HDAC inhibition occurs, selectively involving activation of caspase 8 and effector caspase 3, as well as down-regulation of c-FLIP protein. [6] In 11 of 13 (85%) renal cell carcinoma cell lines and in 16 of 37 (43%) other cancer cell lines, Romidepsin treatment up-regulates tumor death receptors, and potentiates natural killer (NK)-mediated tumor killing. [7] Romidepsin exhibits concentration-dependent cytotoxicity against a panel of mantle cell lymphoma (MCL) cell lines. [9]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 M3G2SmNmdGxiVnnhZoltcXS7IFHzd4F6 Mn\WNk42NTF3IH7N MXu3NkBp NUHHNIt7cW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= MXyyOVc6ODlyNx?=
U2932  NWLzU5c1S2WubDDWbYFjcWyrdImgRZN{[Xl? NYeyPHB2Oi53LUG1JI5O M3;zRlczKGh? M{PJUYlv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? MUmyOVc6ODlyNx?=
OCI-LY7 NGGyXYlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M2\zSFIvPS1zNTDuUS=> MXS3NkBp NVPIToJrcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= MUOyOVc6ODlyNx?=
Farage MYPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MV:yMlUuOTVibl2= NGracG84OiCq M4fZZYlv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? MW[yOVc6ODlyNx?=
LY7/EBV NX7wZXhUS2WubDDWbYFjcWyrdImgRZN{[Xl? NEDvdYkzNjVvMUWgcm0> Mk\rO|IhcA>? M3\LNolv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? NETPRnMzPTd7MEmwOy=>
U2932/EBV MV3D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NITXNmgzNjVvMUWgcm0> Mkn0O|IhcA>? NGXvWXpqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NEPaZmozPTd7MEmwOy=>
HCT116 M{HlVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUS1MVUxODBibl2= MUiyOEBp MoLZSG1UVw>? NFy1doVqdmS3Y3XzJINmdGxiZHXheIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> NWfUS5lSOjV2OUK1NVU>
ACH-2 Mm\2SpVv[3Srb36gRZN{[Xl? NGnNUHMyNTlibl2= MYWyOEBp NHLoOYxqdmS3Y3XzJGhKXi1zIFXuekBmgHC{ZYPzbY9v NX76eWJiOjVzNEm0Olc>
MCF-10A NWDnUFc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjOdlhKSzVyPUCuNVfDuTBwMEGgcm0> M1HkOVI1QTV2OEW2
MCF-7 NIn6do1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fHT2lEPTB;MT6xNOKyOC5{MDDuUS=> M3TEeVI1QTV2OEW2
SK-BR-3 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfWeI5RUUN3ME2xMlAxyrFyLkO1JI5O NGT1VIEzPDl3NEi1Oi=>
MDA-MB-231 NF7ne|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{[0TmlEPTB;MD62POKyOC5zNDDuUS=> M3S5clI1QTV2OEW2
PC3 M122S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjZTWM2OD1zLk[1xtExNjN3IH7N MY[yOFk2PDh3Nh?=
HCT116 M1PkUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfGSFBKSzVyPUGuNFDDuTBwMECgcm0> M3TtPVI1QTV2OEW2
HCT116-p21-/- MorNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PvTmlEPTB;MT6yOuKyOC5|NzDuUS=> Mnn1NlQ6PTR6NU[=
S1 NUW5TY0{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTdwNkhCtVAvOjlibl2= M1nyWlI1QTV2OEW2
SW620 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWr5eHk2UUN3ME2wMlk{yrFyLkK5JI5O NEH5[VIzPDl3NEi1Oi=>
LOX-IMVI NHi0VGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jyVmlEPTB;MD64O:KyOC5yMzDuUS=> NHHad4IzPDl3NEi1Oi=>
UACC-62 NWfNR4hRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwNUdCtVAvOTZibl2= M1P3d|I1QTV2OEW2
MDA-MB-435 NHLmNpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\NWHpUUUN3ME2wMlkxyrFyLkC2JI5O MX2yOFk2PDh3Nh?=
SF-295 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjMZ|hKSzVyPUCuPFjDuTBwMUWgcm0> NYjxU3dIOjR7NUS4OVY>
A549 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTFwMkdCtVAvOjRibl2= M{HRV|I1QTV2OEW2
H460 Mn7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3K1VmlEPTB;Mj61POKyOC56MDDuUS=> MUKyOFk2PDh3Nh?=
EKVX MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nxSWlEPTB;MT6zN:KyOC5|NDDuUS=> MWCyOFk2PDh3Nh?=
H146 M{\TZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DTSmlEPTB;MD6yNuKyOC5yNzDuUS=> NW[1OpQ2OjR7NUS4OVY>
H526 NWHmenRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Tme2lEPTB;MD6xOeKyOC5yMzDuUS=> MXmyOFk2PDh3Nh?=
HuT-78 NFu5dVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2X2eWlEPTB;MT63N:KyOC52NDDuUS=> M1vNUFI1QTV2OEW2
HA NYTUPHl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXHe44xNjZ{NT2xNI5O M4KxRVQ5KGh? M3HqOolv\HWlZYOgZUB{cWewaX\pZ4FvfGy7IIP0do9v\2W{IHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vKGOxLYTy[YF1\WRid3n0bEBjd3K2ZYrvcYlj NFfQPGUzPDd5MUWxNC=>
MS-275 M1jKUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLwNm5mOC54MkWtNVBvVQ>? M1\wfFQ5KGh? NUnmXYdNcW6mdXPld{BiKHOrZ37p[olk[W62bImgd5Rzd26pZYKgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iY3:teJJm[XSnZDD3bZRpKGKxcoTlfo9ucWJ? MX[yOFc4OTVzMB?=
CD4 T NEfXOItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zwTlQ5KGh? NWT4W5ZWTUN3ME20MlXDuTFwMDDuUS=> NILQ[lYzPDd{MkS1OC=>
CD4 T MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTodnY1QCCq M3\vTWNEPTB;MUC3xtEyOjZibl2= MYmyOFczOjR3NB?=
CD4+ T M4TUbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnlN49GSzVyPUOgcm0> NF3LSm0zPDR7NUGwOS=>
A549 M2rOeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULqPZRbOTEkgKOxNFDDqG6P M2\mZ|I1NzN4L{S4JIg> Mo\5bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NXTtfVg1OjR2OEW3PVk>
JJN3 M1nx[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrMbI13OjRxNEigbC=> MoO2SWM2ODxz4pEJcm08KDR64pEJbC=> MWGyOFA{ODF3MB?=
OPM-2 NFzGcHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrtNlQwPDhiaB?= M1XCdWVEPTC|PUJihKlvVTtiNElihKlp M2\0VFI1ODNyMUWw
RPMI-8226 M{DUN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\jWYZnOjRxNEigbC=> MniwSWM2OHN;MT645qCKdk19IES45qCKcA>? M4nyTFI1ODNyMUWw
U266 NITSc|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFztXIkzPC92ODDo NWnEN5lxTUN3MIO9NVDjiImwTUugOFjjiImq NUP2PZM5OjRyM{CxOVA>
CA46 NHPRcYlCeG:ydH;zbZMhSXO|YYm= MWK2JIg> MU\pcoR2[2W|IHLseY51KGGyb4D0c5Nqew>? NYj0Smk{OjN7Nk[xOlQ>
DG75 MWrBdI9xfG:|aYOgRZN{[Xl? M2Hl[VYhcA>? NETqNFJqdmS3Y3XzJI5wKGGyb4D0c5Nqew>? NViyNFdDOjN7Nk[xOlQ>
Ramos NGixbYtCeG:ydH;zbZMhSXO|YYm= MonoOkBp M2nlV4lv\HWlZYOg[Zh1\W6|aY\lJIFxd3C2b4Ppdy=> NVzJS5JxOjN7Nk[xOlQ>
ST486 MUPBdI9xfG:|aYOgRZN{[Xl? NGfVNVk3KGh? M1nY[Ilv\HWlZYOg[Zh1\W6|aY\lJIFxd3C2b4Ppdy=> NUfUXVJuOjN7Nk[xOlQ>
HuT78 NEPJTXVCeG:ydH;zbZMhSXO|YYm= NGr5PZMyNzFyL{GwNEBvVQ>? NVq1SYtyPDhiaB?= NViyclZFcW6mdXPld{BieG:ydH;zbZMh[XRiMTDuUS=> MoroNlM2OzJ5M{K=
DpVp35 MlTJRZBweHSxc3nzJGF{e2G7 MXixM|ExNzFyMDDuUS=> NF;KWHU1QCCq NF7qdGhqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= NUnMUpdFOjN3M{K3N|I>
DpVp50 Mle0RZBweHSxc3nzJGF{e2G7 NI\iUGQyNzFyL{GwNEBvVQ>? M{LadFQ5KGh? NUHxeXR5cW6mdXPld{BjdHWwdDDhdI9xfG:|aYO= M3i4UFI{PTN{N{Oy
DpP75  NXrhUJJ{SXCxcITvd4l{KEG|c3H5 MUSxM|ExNzFyMDDuUS=> NXrjO|g3PDhiaB?= NFTlZlVqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= NV3RcHJvOjN3M{K3N|I>
SKOV-3 MnTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\wO5dGOeLCk{Kwcm0> NFe3XpY4OiCq MWLEUXNQ M4XpUpJm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv M1LlXFI{ODFyM{S4
Brca1 WT MnHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nCTVHjiJN{MH7N MmjXO|IhcA>? NUTxSFlnTE2VTx?= M{T3SZJm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv NWPhcZdZOjNyMUCzOFg>
Brca1 Null MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjrSmZ2OeLCk{Kwcm0> NUjLdGpUPzJiaB?= MVzEUXNQ NHzZ[5dz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? M1rGOVI{ODFyM{S4
OVCAR-8  MnuxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvNeYoy6oDVMkDuUS=> MoDaO|IhcA>? MWLEUXNQ MXny[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGGub37lJIFv\CClb33ibY5m\CC5aYToJINqe3CuYYTpci=> Ml7uNlMxOTB|NEi=
NCI/ADR-RES M3z0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfUNgKBmzJybl2= MnHWO|IhcA>? NHTHem5FVVOR MkHLdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> M33ITFI{ODFyM{S4
HCT116 MknFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGP5PIs2KG6PLUWwJO69VQ>? MWGyOEBp NInFeHdFVVOR MX;pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> M2jobVIzQTJ2OUW4
RKO Ml3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHPPXJbPSCwTT21NEDPxE1? MYKyOEBp M2PLT2ROW09? NXvCTHVEcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? M1y1clIzQTJ2OUW4
CO115 M3rXb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVK1JI5ONTVyIN88US=> NWnjZmh5OjRiaB?= NULuc2k4TE2VTx?= M4PnVIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz MXqyNlkzPDl3OB?=
HFS MlHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWS1JI5O M4DMVlI1NzR6L{eyJIg> MWDpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nLXTldIVv\GWwdHz5 MnW2NlIyODZ{OEK=
LNCaP MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWS1JI5O M{GwO|I1NzR6L{eyJIg> MVjpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nLXTldIVv\GWwdHz5 M13pfFIzOTB4Mkiy
A549 Ml3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWK1JI5O MoL2NlQwPDhxN{KgbC=> MVXpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nLXTldIVv\GWwdHz5 NXP1enNpOjJzME[yPFI>
697  MoDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofzTWM2OOLCiU5ihKkzNjYEoH7N M1rEXVIyPTN6MkG2
697-R M3fa[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|Ux6oDLPfMAjVgvPsLibl5CpC=> NX;DcokxOjF3M{iyNVY>
HUT78 NUT5elZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEX5V5VKSzVyPUGgcm0> M3LBWlIyOTl6NUS1
THJ-16T NWT0NHJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHYOmVrOSCwTR?= M37jXlI1KGh? NVTNfGNucW6qaXLpeJMh[2WubDDndo94fGh? M{HLV|IxQDFyNU[4
HCT116 NFmwT41HfW6ldHnvckBCe3OjeR?= M4TxeVIxKG6P MXu4JIg> NWDuZoRPdW:mdXzheIV{KHS{YX7zZ5JqeHRibHX2[Yx{KG[xcjDoeY5lemWmczDv[kBo\W6nczDpckBmcXSqZYKg[Ilz\WO2aX;u NGLxO3QzODd|OUS1OC=>
B104  NX[xPVNmTnWwY4Tpc44hSXO|YYm= NYOwOZNTOiCwTR?= NU\iNHZlOjRxNEivO|IhcA>? M4C4Zolv[3KnYYPld{B1cGVic4Xy[oFk\SCneIDy[ZN{cW:wIH;mJGNFOjEEoB?= M3r1fVIxPjh4NUC1
HL-60  NGHqWVdEgXSxdH;4bYNqfHliQYPzZZk> MYWxMVUxOCCwTR?= NHHiXFMzPCCq NYrpPGMzcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= MlThNlA3OjRzNkO=
HP100 NXux[JJmS3m2b4TvfIlkcXS7IFHzd4F6 M1HxUlEuPTByIH7N NWTWdFRnOjRiaB?= NVy2ToFucW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= MmHPNlA3OjRzNkO=
HL-60  MVHGeY5kfGmxbjDBd5NigQ>? NIPhWGsyOCCwTR?= MVq0M|YwOTZiaB?= NEP4SYlqdmS3Y3XzJJRp\SCpZX7ldoF1cW:wIH;mJIh6\HKxZ3XuJJBmem:6aXTlJIZzd21iNHi= MneyNlA3OjRzNkO=
HP100 M2rqVmZ2dmO2aX;uJGF{e2G7 M{\jUlExKG6P MoTCOE83NzF4IHi= NYDuN5ZzcW6mdXPld{B1cGViZ3Xu[ZJifGmxbjDv[kBpgWS{b3flckBx\XKxeHnk[UBnem:vIETo MXqyNFYzPDF4Mx?=
HL-60  M{TDfGZ2dmO2aX;uJGF{e2G7 NVrxbHJOOTBvNUCwJI5O NG\YPXQ1KGh? MVHk[YNz\WG|ZYOgeIhmKGirc4TvcoUh\GWjY3X0fYxie2ViKFjERWMqKGGldHn2bZR6yqB? NV36TWhYOjB4MkSxOlM>
HP100 MlP2SpVv[3Srb36gRZN{[Xl? NXjGTWtVOTBvNUCwJI5O NGHzPZA1KGh? MXfk[YNz\WG|ZYOgeIhmKGirc4TvcoUh\GWjY3X0fYxie2ViKFjERWMqKGGldHn2bZR6yqB? MlvaNlA3OjRzNkO=
11z MoTXT4lv[XOnIFHzd4F6 MXyzMVExOCCwTR?= NET3NGtz\WS3Y3XzJGhFSUNiZX76fY1ifGmlIHHjeIl3cXS7IDjJR|UxyqB;IE[uOUDDuSByLk[gco1wdC:OKR?= M{DzNFIxPjB3MUS0
SKOV-3 M3i5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLsRWc1NzhxMU[gcm0> MX20PEBp NH72dYdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? NGrJbVEzODRyNEW2OC=>
OVCAR-3 M4nyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLQOE85NzF4IH7N NFHSb3o1QCCq NF7UfJJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? MVGyNFQxPDV4NB?=
HBL-2 NH22foJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjuRo4zNTFyIH7N MYmyOEBp NEPjc3lKSzVyPUSuN{BvVQ>? NFjS[VYzODB4OEC4NC=>
Jeko-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDBOItpOi13MDDuUS=> MkSzNlQhcA>? NGH2ZWtKSzVyPUGxJI5O M{joPVIxODZ6MEiw
Granta-519 MmXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHT6c|M2NTRyIH7N NG\2ZowzPCCq MorxTWM2OD13OD61JI5O MX[yNFA3QDB6MB?=
L1236 M17DNGN6fG:2b4jpZ4l1gSCDc4PhfS=> M4DuelEhdk1vMUCwJO69VQ>? NH2z[2w1QCCq MVjFR|UxRTBwMEeg{txO NGK1dYIyQTJ|M{S3NC=>
L428 NXzPWXFbS3m2b4TvfIlkcXS7IFHzd4F6 MUWxJI5ONTFyMDFOwG0> Mli2OFghcA>? MWrFR|UxRTBwNEOg{txO MmjHNVkzOzN2N{C=
KM-H2 MVrDfZRwfG:6aXPpeJkhSXO|YYm= NITzVIcyKG6PLUGwNEDPxE1? MlLlOFghcA>? NWLZSlJ4TUN3ME2wMlU5KM7:TR?= MYOxPVI{OzR5MB?=
L540Cy M4LOSGN6fG:2b4jpZ4l1gSCDc4PhfS=> MUSxJI5ONTFyMDFOwG0> M{fNO|Q5KGh? NIGyVllGSzVyPUCuNVYh|ryP M1myXVE6OjN|NEew
G401 NFzPZ5FHfW6ldHnvckBCe3OjeR?= NG\ZW|gyOCCwTR?= MVSyOE81QC95MjDo MmXTSG1UVw>? NVXyWJk6cW6lcnXhd4V{KEOGS16xR{BmgHC{ZYPzbY9v M3;sRVE6OjJzNUi2
STM91-01 Ml7USpVv[3Srb36gRZN{[Xl? MVGxNEBvVQ>? MYCyOE81QC95MjDo MoHBSG1UVw>? M{TncIlv[3KnYYPld{BETEuQMVOg[ZhxemW|c3nvci=> MVixPVIzOTV6Nh?=
SJSC  MmW5SpVv[3Srb36gRZN{[Xl? M1TRWVExKG6P MVqyOE81QC95MjDo MnSzSG1UVw>? MlTGbY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;u MYKxPVIzOTV6Nh?=
BT16  MWXGeY5kfGmxbjDBd5NigQ>? M2LI[FExKG6P NGLIRXIzPC92OD:3NkBp NH\FTJhFVVOR MYjpcoNz\WG|ZYOgR2RMVjGFIHX4dJJme3Orb36= MYWxPVIzOTV6Nh?=
NCI-H1299 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLvR5ZLUUN3ME20MlbDuTBwMjDu[{9udA>? NGrIUWsyQTF5OUi5NC=>
NCI-2882 NHPBd3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTFwNtMxNE4xPCCwZz;tcC=> MWexPVE4QTh7MB?=
HCC95 NGfKPIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jDRmlEPTB;Mj61xtExNjB3IH7nM41t M3SxfVE6OTd7OEmw
NCI-H23 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4O5XmlEPTB;Mj65xtExNjJibnevcYw> NVrSOIp7OTlzN{m4PVA>
NCI-H157 NVPtZ3lzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDVWnZrUUN3ME2xMlbDuTBwMEKgcocwdWx? NIrKWJcyQTF5OUi5NC=>
NCI-H460 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17XNWlEPTB;Mj6xxtExNjB5IH7nM41t M3\rSVE6OTd7OEmw
NCI-H1975 NV\zdXVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPMUHpKSzVyPUGuN:KyOC5yNDDu[{9udA>? NUDUSVBEOTlzN{m4PVA>
NCI-H820 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrCTpBKSzVyPUKuOOKyOC5zIH7nM41t MXmxPVE4QTh7MB?=
NCI-H1650 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTRwOdMxNE4{KG6pL33s NY\NXIExOTlzN{m4PVA>
DTC1 NGT4cFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HMZ2lEPTB;MD61NUBvVQ>? NIHPSY0yQDV4NkK0Oi=>
KAO MmTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TUPGlEPTB;MD65NUBvVQ>? NHjGRZUyQDV4NkK0Oi=>
SU-CCS-1 M{\CZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfMTWM2OD1yLki5JI5O NWLXe5Z7OTh3Nk[yOFY>
SYO-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrJU5RKSzVyPUCuOlchdk1? NEG3dGYyQDV4NkK0Oi=>
FUJI NH\ISJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHDUJhKSzVyPUGuN|Ehdk1? Mn30NVg2PjZ{NE[=
SKNMC MkDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LUZWlEPTB;MT6xO{BvVQ>? MVexPFU3PjJ2Nh?=
402-91 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jBOmlEPTB;MT6yOkBvVQ>? MojoNVg2PjZ{NE[=
1765-92 NGrmS|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTFwN{egcm0> MlLpNVg2PjZ{NE[=
JN-DSRCT-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfOepFLUUN3ME2xMlI2KG6P NGj4SngyQDV4NkK0Oi=>
NMS-2PC MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwOEGgcm0> MVKxPFU3PjJ2Nh?=
HL60 MnOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFmzOopKSzVyPUGuPFYhdk1? MnfDNVg2PjZ{NE[=
A549 MmixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnUfHlKSzVyPUOuNlQhdk1? M3LnXVE5PTZ4MkS2
SW480 MnHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnNWY1[UUN3ME2yMlY6KG6P MXuxPFU3PjJ2Nh?=
MCF7 NVXTNHh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfxc3JKSzVyPUOuOVUhdk1? NI\2PW0yQDV4NkK0Oi=>
PC-3 M4nKZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDy[mFjUUN3ME2yMlUyKG6P NGfPboEyQDV4NkK0Oi=>
MMRU MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TIR2lEPTB;Mj61O{BvVQ>? Mmi5NVg2PjZ{NE[=
Hs68 NHLTd4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRT5zMDDuUS=> NFTqe5cyQDV4NkK0Oi=>
hMSC-001F MnWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoKzTWM2OD1-MUCgcm0> MkjzNVg2PjZ{NE[=

... Click to View More Cell Line Experimental Data

In vivo Romidepsin treatment potently inhibits the neovascularization of chick embryo and that of adult mice in the Matrigel plug assay. [4]Administration of Romidepsin at 0.1-1 mg/kg twice a week significantly prolongs the survival of mice bearing U-937 lymphoma, with median survival times of 30.5 (0.56 mg/kg) and 33 days (0.32 mg/kg), respectively (vs. 20 days in control mice). [5]

Protocol

Kinase Assay:

[1]

+ Expand

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
Cell Research:

[3]

+ Expand
  • Cell lines: HL60, Jurkat, A549, and MCF-7
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Romidepsin for 72 hours in 96-well plates. 20 μL of 5 mg/mL MTT solution in PBS is added to each well for 4 hours. After removal of the medium, 170 μL of DMSO is added to each well to dissolve the formazan crystals. The absorbance at 540 nm is determined. In addition, cells are incubated with trypan blue, and the numbers of blue (dead) cells and transparent (live) cells are counted in a hemocytometer. For cell cycle analysis, cells are incubated for 30 minutes in propidium iodide staining solution containing 0.05 mg/mL propidium iodide, 1 mM EDTA, 0.1% Triton X-100, and 1 mg/mL RNase A in PBS. The suspension is then passed through a nylon mesh filter and analyzed on a Becton Dickinson FACScan.


    (Only for Reference)
Animal Research:

[5]

+ Expand
  • Animal Models: Male scid mice inoculated i.p. with U-937 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~1 mg/kg once or twice a week
  • Administration: Treated i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 10 mg/mL (18.49 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
2% DMSO+30% PEG 300+5%Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 540.7
Formula

C24H36N4O6S2

CAS No. 128517-07-7
Storage powder
Synonyms FR 901228, NSC 630176

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00048334 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 26, 2002 Phase 1
NCT00094978 Terminated Carcinoma, Small Cell|Carcinoma, Non-Small-Cell Lung|Esophageal Neoplasms|Mesothelioma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 25, 2004 Phase 1
NCT01445340 Terminated Mycosis Fungoides|Cutaneous T-Cell Lymphoma|Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 21, 2007 Phase 1
NCT02616965 Not yet recruiting Cutaneous T-cell Lymphoma (CTCL) Fox Chase Cancer Center|Seattle Genetics, Inc.|Celgene Corporation April 2017 Phase 1
NCT02850016 Recruiting Human Immunodeficiency Virus (HIV) Rockefeller University|University Hospital of Cologne|Aarhus University Hospital December 2016 Phase 2
NCT02757248 Withdrawn PTCL|CTCL Anne Beaven, MD|National Comprehensive Cancer Network|Boehringer Ingelheim|Duke University November 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) supplier | purchase Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) cost | Romidepsin (FK228, Depsipeptide) manufacturer | order Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID